Precision Biosciences Financial Results
Precision BioSciences reported Q3 2026 financial results, highlighting a cash position of $108 million which is expected to fund operations through 2028. The company advanced its clinical pipeline, including dosing the first patient in the Phase 1/2 FUNCTION-DMD study and preparing for a late-breaking oral presentation of PBGENE-HBV data at AASLD's The Liver Meeting.
“We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress executing against that plan. In the third quarter, we continued to advance PBGENE-HBV in the ELIMINATE-B trial for chronic hepatitis B and are very excited about the opportunity to present important clinical data in a late-breaking oral presentation at the upcoming AASLD Liver Meeting on November 8th at 2:15pm MST.”
Michael Amoroso, Chief Executive Officer of Precision BioSciences
“The third quarter also marked an important milestone for Precision BioSciences and more importantly for the children who live with Duchenne muscular dystrophy (DMD). Our team alongside our investigators commenced dosing of the first patient in the FUNCTION-DMD trial.”
Michael Amoroso, Chief Executive Officer of Precision BioSciences